Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on April 23, 2025
Best Magnesium Supplements for Weight Loss 2025: Benefits, Dosage & Types Explained - by bioptimizers
GlobeNewswire
·
April 23, 2025
Kietzke Lane, April 23, 2025 (GLOBE NEWSWIRE) -- Magnesium is one of the few minerals that the body uses over 300 times a day. Magnesium is charged with energy production and muscle contraction to a normal heartbeat and clear thinking. Millions of people …
Comprehensive Mental Health Care: NJ Chef-Turned-Health Care Provider Blends Medication, Therapy, And Holistic Strategies To Treat Patients
GlobeNewswire
·
April 23, 2025
BASKING RIDGE, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- For the past two years, board-certified psychiatric nurse practitioner and professional chef, William Chu, has dedicated his practice, MindSync Psychiatry, to providing comprehensive, patient-centered …
Science Translational Medicine Study Funded by the Bay Area Lyme Foundation Identifies FDA-approved Piperacillin as More Effective, Targeted Treatment for Lyme Disease
GlobeNewswire
·
April 23, 2025
PORTOLA VALLEY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces two pre-clinical studies published in the peer-reviewed journal Science Translational Medicine. The studies …
SynoGut Reviews (ALERT) Consumer Reports Reveal Unexpected Truths Behind Its Ingredients And Side Effects
GlobeNewswire
·
April 23, 2025
CANTON, Ohio, April 23, 2025 (GLOBE NEWSWIRE) -- SynoGut is a gut health support supplement that provides a natural way to support a healthy digestive system. The dietary formula is a combination of natural herbs, vitamins, and minerals that are clinically …
Pineal XT Reviews (WARNING) Is It Safe And Worth Trying? Understanding Its Natural Ingredients And Benefits!
GlobeNewswire
·
April 23, 2025
ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Pineal XT is a natural dietary capsule developed and designed to support cognitive functions. It blends in scientifically proven ingredients to enhance brain power, improve mood, stimulate the pineal gland, …
Prime Biome Reviews (We Tried It for 115 Days) Here’s Our Month-by-Month Review, Unexpected Results, And Benefits!
GlobeNewswire
·
April 23, 2025
ALBANY, N.Y., April 23, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a dietary supplement designed to support skin and gut health by achieving microbial equilibrium in the body. It is loaded with probiotics for clear skin and anti-aging vitamins that can combat …
John Flack Appointed CFO of Advanced Medical Pricing Solutions
GlobeNewswire
·
April 23, 2025
PHOENIX, April 23, 2025 (GLOBE NEWSWIRE) -- Advanced Medical Pricing Solutions (“AMPS”), a diversified healthcare technology company supporting transparent, affordable medical and prescription benefits, announced today the appointment of John A. Flack II …
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight
GlobeNewswire
·
April 23, 2025
New York, USA, April 23, 2025 (GLOBE NEWSWIRE) -- Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight The liquid biopsy market size in cancer diagnostics is experiencing …
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
GlobeNewswire
·
April 23, 2025
PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science SA (Euronext - FR0010557264 - AB) announces today …
La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue
GlobeNewswire
·
April 23, 2025
COMMUNIQUE DE PRESSE LA MOLECULE AB8939 OBTIENT LA DESIGNATION DE MEDICAMENT ORPHELIN DANS L’UNION EUROPEENNE AUPRES DE L’AGENCE EUROPEENNE DES MEDICAMENTS (EMA) DANS LE TRAITEMENT DE LA LEUCEMIE MYELOÏDE AIGUE Paris, 23 avril 2025, 18h45 AB Science SA ( …
MJH Life Sciences® and the American College of Cardiology collaborate to advance pharmacists’ role in cardiovascular care through education and clinical collaboration
GlobeNewswire
·
April 23, 2025
CRANBURY, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- MJH Life Sciences® announces a Strategic Alliance Partnership (SAP) between the American College of Cardiology (ACC) and two MJH premier brands, Pharmacy Times® (PT) and Pharmacy Times Continuing Education …
Global Non-Invasive Surgical Wound Closure Market Poised to Reach USD 3,696.2 Million by 2035 at a CAGR of 4.1% | FMI
EIN Presswire
·
April 23, 2025
United States is anticipated to remain at the forefront in North America, with a value share of 58.7% through 2035. China is witness a CAGR of 5.8% by 2035. NEWARK, DE, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- The global non-invasive surgical …
Mobile Clinic Market is likely to reach USD 6.7 Billion by 2034, Driven by Healthcare Accessibility Initiatives | FMI
EIN Presswire
·
April 23, 2025
Mobile clinics serve to solve healthcare deserts, especially in rural or distant places where standard healthcare services are limited. NEWARK, DE, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- The global mobile clinic market is undergoing a …
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025
GlobeNewswire
·
April 23, 2025
OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025 Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer Ingelheim NANTES, France – April 23, 2025, 6:00 p.m. CET - OSE …
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025
GlobeNewswire
·
April 23, 2025
OSE Immunotherapeutics annonce la sélection de plusieurs abstracts pour présentation à l’ASCO 2025 Présentations sur l’actif propriétaire Tedopi® et sur deux inhibiteurs de SIRPα développés en partenariat avec Boehringer Ingelheim NANTES, France, 23 avril …
Artax Biopharma to present Phase 2a data on Nck modulator AX-158, establishing novel mechanism of action in autoimmune disease at the 2025 SID Annual Meeting
GlobeNewswire
·
April 23, 2025
Late breaker abstract presentation to showcase clinical validation of first-in-class oral small molecule AX-158 in cohort of patients with psoriasis Full dataset to expand on previously announced topline results, reinforcing the potential of Nck modulation …
AAPA 2025 Opening General Session to Explore How Technology Is Reshaping Patient Care
GlobeNewswire
·
April 23, 2025
Alexandria, Va., April 23, 2025 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) will explore how innovation is helping medical providers address today’s top healthcare issues and improve patient outcomes during AAPA 2025’s opening …
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC …
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
GlobeNewswire
·
April 23, 2025
ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeutics announced today an oral presentation at the upcoming …
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
·
April 23, 2025
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 ( …